Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-risk neuroblastoma

Clinical Trial Protocol

University Hospital Regensburg

Sponsor’s Protocol No: RIST-rNB-2011
EudraCT No.: 2011-004062-15
ClinicalTrials.gov Identifier: NCT01467986

Study drugs: Rapamycin, Dasatinib, Temozolomide, Irinotecan
Version: 4.0
Status: Final
Date: 03.01.2014